Current Progress in Antifibroitcs
Authors: A.A. El Bialy, S.; F. Abd El Kader, K.; B. El-Ashmawy, M.
Source: Current Medicinal Chemistry, Volume 18, Number 20, July 2011 , pp. 3082-3092(11)
Publisher: Bentham Science Publishers
Abstract:After years of viewing cirrhosis as the irreversible end-stage of liver fibrosis, it has been shown recently that the possibility of its reversal is no longer a dream. Several studies on experimental animal models showed possible spontaneous resolution of fibrosis after the removal of fibrogenic stimulus. Similar results were also observed in human patients with liver fibrosis due to autoimmune hepatitis and biliary etiology. However, the need for other means of treatment is urgent, especially when the removal of the causative factor is unlikely. Recent antifibrotic strategies were designed to target one or more of the three stages involved in the process of fibrosis. These are the triggering stage, fibrogenesis, and extracellular matrix accumulation. In this review, the classification of the current drugs or agents that showed inhibition of one or more of fibrosis stages with their chemical synthesis are presented.
Keywords: Antifibrotics; Hepatic stellate cells (HSC); MMPs; Prolyl-4-hydroxylase; cirrhosis; epigenetic therapy; extracellular matrix accumulation; fibrogenesis; fibrogenesis inhibitors; fibrogenesis triggers; fibrosis
Document Type: Research Article
Publication date: July 1, 2011
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.